Author(s):
Anju govind, Manjunath B Menden, Ravikumar, Simila1, Mercy, Narayana Swamy VB
Email(s):
ravikumar300@gmail.com
DOI:
10.5958/2231-5713.2016.00013.1 
Address:
Anju govind1, Manjunath B Menden2, Ravikumar2*, Simila1, Mercy1, Narayana Swamy VB3
1M.Pharam (Pharmaceutics) Research Scholar, Karavli College of Pharmacy, Mangalore.
2Department of Pharmaceutics, Karavali College of Pharmacy, Vamanjoor, Mangalore.
3Department of Pharmacognosy, Karavali College of Pharmacy, Vamanjoor, Mangalore.
*Corresponding Author
Published In:
Volume - 6,
Issue - 2,
Year - 2016
ABSTRACT:
The present investigation of research is oriented through increasing safety and efficacy of existing drug molecule through novel concept of oral drug delivery Deflazacort is a synthetic steroid that has an anti inflammatory effect. It is used to decrease inflammation in various different diseases and conditions. Deflazacort works by acting within cells to prevent the release of certain chemicals that are important in the immune system. These chemicals are normally involved in producing immune and allergic responses; resulting in inflammation. By decreasing the release of these chemicals in a particular area, inflammation is reduced. This can help control a wide number of disease states characterized by excessive inflammation. These include severe allergic reactions, inflammation of the lungs in asthma and inflammation of the joints in arthritis.
Deflazacort also decreases the numbers of white blood cells circulating in the blood. And patients Nephritic Syndrome, required steroids for long times. Mouth dissolving tablets of Deflazacort were prepared by Superdisintegrant addition method using SSG, and Croscarmellose sodium as superdisintegrants at 5-10% w/w, showed minimum time to disintegrate the tablet (20.13 sec.) and almost complete release of drug within 15 minutes. The optimized formulation F14 was chosen and their optimum results were found to be in close agreement with experimental finding. The FTIR studies for the optimized formulation F14 shows that there was no interaction between drug and excipients. The stability studies for the optimized formulation F14 showed no significant changes.
Cite this article:
Anju govind, Manjunath B Menden, Ravikumar, Simila1, Mercy, Narayana Swamy VB. Formulation and Evaluation of Mouth Dissolving Tablets of Deflazacort. Asian J. Pharm. Tech. 2016; 6(2): 91-98. doi: 10.5958/2231-5713.2016.00013.1
Cite(Electronic):
Anju govind, Manjunath B Menden, Ravikumar, Simila1, Mercy, Narayana Swamy VB. Formulation and Evaluation of Mouth Dissolving Tablets of Deflazacort. Asian J. Pharm. Tech. 2016; 6(2): 91-98. doi: 10.5958/2231-5713.2016.00013.1 Available on: https://ajptonline.com/AbstractView.aspx?PID=2016-6-2-5